6.The effect of probiotics supplementation in postoperative cancer patients: a prospective pilot study
Hyeji KWON ; Song Hwa CHAE ; Hyo Jin JUNG ; Hyeon Min SHIN ; O-Hyun BAN ; Jungwoo YANG ; Jung Ha KIM ; Ji Eun JEONG ; Hae Myung JEON ; Yong Won KANG ; Chan Kum PARK ; Daeyoun DAVID WON ; Jong Kyun LEE
Annals of Surgical Treatment and Research 2021;101(5):281-290
Purpose:
Microbiota manipulation through selected probiotics may be a promising tool to prevent cancer development as well as onset, to improve clinical efficacy for cancer treatments. The purpose of this study was to evaluate change in microbiota composition after-probiotics supplementation and assessed the efficacy of probiotics in improving quality of life (QOL) in postoperative cancer patients.
Methods:
Stool samples were collected from 30 cancer patients from February to October 2020 before (group I) and after (group II) 8 weeks of probiotics supplementation. We performed 16S ribosomal RNA gene sequencing to evaluate differences in gut microbiota between groups by comparing gut microbiota diversity, overall composition, and taxonomic signature abundance. The health-related QOL was evaluated through the EORTC Quality of life Questionnaire Core 30 questionnaire.
Results:
Statistically significant differences were noted in group II; increase of Shannon and Simpson index (P = 0.004 and P = 0.001), decrease of Bacteroidetes and Fusobacteria at the phylum level (P = 0.032 and P = 0.014, retrospectively), increased of beneficial bacteria such as Weissella (0.096% vs. 0.361%, P < 0.004), Lactococcus (0.023% vs. 0.16%, P < 0.001), and Catenibacterium (0.0% vs. 0.005%, P < 0.042) at the genus level. There was a significant improvement in sleep disturbance (P = 0.039) in group II.
Conclusion
Gut microbiota in cancer patients can be manipulated by specific probiotic strains, result in an altered microbiota. Microbiota modulation by probiotics can be considered as part of a supplement that helps to increase gut microbiota diversity and improve QOL in cancer patients after surgery.
7.Cyanide toxicity during cardiopulmonary bypass with small dose of nitroprusside: a case report.
Kum Hee CHUNG ; Seo Min PARK ; In Chan BAEK ; Junheum JANG ; Yong Woo HONG ; So Woon AHN
Korean Journal of Anesthesiology 2016;69(2):181-184
Sodium nitroprusside (SNP) is an anti-hypertensive drug, commonly used to decrease the systemic vascular resistance and lower the blood pressure. When the amount of cyanide generated by the SNP exceeds the metabolic capacity for detoxification, cyanide toxicity occurs. Under general anesthesia and cardiopulmonary bypass (CPB), it may be difficult to detect the development of cyanide toxicity. In cardiac surgical patients, hemolysis, hypothermia and decreased organ perfusion, which emphasize the risk of cyanide toxicity, may develop as a consequence of CPB. In particular, hemolysis during CPB may cause an unexpected overproduction of cyanide due to free hemoglobin release. We experienced a patient who demonstrated SNP tachyphylaxis and cyanide toxicity during CPB, even though the total amount of SNP administered was much lower than the recommended dose. We therefore report this case with a review of the relevant literature.
Anesthesia, General
;
Blood Pressure
;
Cardiopulmonary Bypass*
;
Cyanides
;
Hemolysis
;
Humans
;
Hypothermia
;
Nitroprusside*
;
Perfusion
;
Tachyphylaxis
;
Vascular Resistance
8.A Case of Myeloid Sarcoma of Intestine.
Sung Won LIM ; Hang Lak LEE ; Kang Nyeong LEE ; Dae Won JUN ; In Young KIM ; Eunjin KIM ; Hyein AHN ; Chan Kum PARK
The Korean Journal of Gastroenterology 2016;68(3):148-151
Myeloid sarcoma (MS) is an extramedullary involvement of immature myeloid proliferation. An isolated MS is defined as a myeloblastic tumor when it arises without any concomitant circulating disease. A diagnosis of MS is established using pathologic features including infiltration of myeloblasts and strong myeloperoxidase expression with negative cytokeratin immunohistochemical staining. We report a rare case of colonic MS without any peripheral blood abnormality. If the affected patient were left untreated, the MS could evolve into acute myeloid leukemia (AML) within one year. Several studies recommend the same regimens of chemotherapy as used for circulating AML to treat isolated MS. We focused on the diagnosis of MS in this study. The correct diagnosis of MS is important for adequate treatment. In conclusion, MS should be considered in the differential diagnosis of intestinal tumor.
Colon
;
Colonic Neoplasms
;
Diagnosis
;
Diagnosis, Differential
;
Drug Therapy
;
Granulocyte Precursor Cells
;
Humans
;
Intestines*
;
Keratins
;
Leukemia, Myeloid, Acute
;
Peroxidase
;
Sarcoma, Myeloid*
9.A Novel F45S SOD1 Mutation in Amyotrophic Lateral Sclerosis Coexisting with Bullous Pemphigoid.
Seong Il OH ; Jeong Ho HONG ; Byung Woo CHOI ; Ki Wook OH ; Chan Kum PARK ; Min Jung KWON ; Chang Seok KI ; Joo Yeon KO ; Seung Hyun KIM
Journal of Clinical Neurology 2015;11(4):390-394
BACKGROUND: The coexistence of an autoimmune disease and amyotrophic lateral sclerosis (ALS) has led to the hypothesis that immune-mediated pathological mechanisms are overlapping in the two diseases. We report herein a rare coexistence of bullous pemphigoid (BP) in a novel mutation (F45S) of the gene encoding Cu/Zn superoxide dismutase (SOD1) in an ALS patient, and discuss a role for the SOD1 mutation in this unusual overlap. CASE REPORT: A 57-year-old male with familial ALS, including vesicles and tense bullae on erythematous bases, was diagnosed with BP. Direct immunofluorescence revealed deposits of C3 and immunoglobulin G in the basement membrane zone. Direct sequencing of SOD1 in the patient revealed a novel mutation (c.137T>C; F45S). CONCLUSIONS: We report a novel SOD1 mutation in ALS, which was combined with BP. This novel SOD1 mutation could affect the phenotype of a combined autoimmune disease and matrix metalloproteinase-9. There may therefore be common factors linking BP and ALS with the SOD1 mutation.
Amyotrophic Lateral Sclerosis*
;
Autoimmune Diseases
;
Autoimmunity
;
Basement Membrane
;
Fluorescent Antibody Technique, Direct
;
Humans
;
Immunoglobulin G
;
Male
;
Matrix Metalloproteinase 9
;
Middle Aged
;
Pemphigoid, Bullous*
;
Phenotype
;
Superoxide Dismutase
;
Transcutaneous Electric Nerve Stimulation
10.Increased Expression of Forkhead Box M1 Is Associated with Aggressive Phenotype and Poor Prognosis in Estrogen Receptor-Positive Breast Cancer.
Hyein AHN ; Jongmin SIM ; Rehman ABDUL ; Min Sung CHUNG ; Seung Sam PAIK ; Young Ha OH ; Chan Kum PARK ; Kiseok JANG
Journal of Korean Medical Science 2015;30(4):390-397
Fox transcription factors play a critical role in the regulation of a variety of biological processes. While FoxM1 behaves like the oncogenic transcription factor, FoxO3a is known as a tumor suppressor by inhibiting FoxM1. This study aimed to investigate the clinicopathological significance of FoxM1 and FoxO3a expression in breast cancer. Expression of FoxM1 and FoxO3a were analyzed by immunohistochemical staining on tissue microarray sections from 236 breast cancer patients, and correlated with various clinicopathological characteristics. Overexpression of FoxM1 correlated with adverse clinicopathological features, such as larger tumor size, lymph node metastasis, advanced tumor stage, and lymphovascular invasion. The Kaplan-Meier survival curves revealed no prognostic significance of FoxM1 expression. However, in subgroup analyses with patients of estrogen receptor (ER) positive breast cancers, FoxM1 overexpression associated with poor disease free and overall survival. No association was found between FoxO3a and FoxM1 expression. Regarding clinicopathological variables, the only association between histologic grade and FoxO3a was observed. In conclusion, FoxM1 overexpression was significantly associated with aggressive phenotypes and poor prognosis of ER-positive breast cancer. These findings suggest the possible role of FoxM1 as a prognostic biomarker and putative target of anti-cancer therapy.
Breast Neoplasms/chemistry/mortality/*pathology
;
Female
;
Forkhead Transcription Factors/*analysis
;
Humans
;
Phenotype
;
Prognosis
;
Receptor, ErbB-2/analysis
;
Receptors, Estrogen/*analysis

Result Analysis
Print
Save
E-mail